ABL1 and gastrointestinal stromal tumor: Imatinib, a specific tyrosine kinase inhibitor that targets the BCR‐ABL, KIT and PDGFR receptors, is used to treat various cancers, including but not limited to chronic myeloid leukaemia and gastrointestinal stromal tumours.44